{"created":"2023-06-19T10:30:05.311971+00:00","id":2179,"links":{},"metadata":{"_buckets":{"deposit":"eec76bde-bca7-44d0-8ab5-dedc623f011d"},"_deposit":{"created_by":31,"id":"2179","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"2179"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00002179","sets":["1709617079800:35:686"]},"author_link":["109813","109814","109815","109816","109817","109818","109819","109820","109821","109822"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"120","bibliographicPageStart":"111","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_33":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著論文","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Regular Article","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"川崎医学会","subitem_publisher_language":"ja"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J201945111","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2019/KMJ-J201945111.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_relation_35":{"attribute_name":"医中誌ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"2020200384","subitem_relation_type_select":"ICHUSHI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_10001_text_31":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学泌尿器科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学泌尿器科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学泌尿器科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学泌尿器科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学泌尿器科学"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　In this study, the serum carnitine level was measured before and after chemotherapy for urologic cancer, and its correlation with QOL was examined. The effect of levocarnitine on chemotherapy-induced QOL reduction was also investigated.\n　The subjects were 17 patients with urologic cancer who received chemotherapy or molecular targeted drug therapy at our department between June 1, 2016 and September 30, 2018. The serum carnitine level was measured before and after therapy. Levocarnitine hydrochloride 1,500 mg/day was then administered orally, and QOL was prospectively evaluated. The serum free carnitine level was measured at 4 time-points: before therapy, after 3 months of therapy, and 1 and 3 months after initiation of levocarnitine hydrochloride. QOL was evaluated based on the global fatigue score (GFS) using the Brief Fatigue Inventory (BFI).\n　The subjects had a median age of 69 years old (52-82 years old) and the male:female ratio was 12:5. The disease was urothelial carcinoma in 10 patients, prostate cancer in 5, and renal cancer in 2. Chemotherapy of gemcitabine/cisplatin for urothelial carcinoma was administered in 10 patients, docetaxel for prostate cancer in 3, cabazitaxel in one, and etoposide/cisplatin in one; and a molecular targeted drug (sunitinib, pazopanib) for renal cancer was used in 2 patients. The free carnitine levels before and after chemotherapy were 49.0±12.1μmol/L and 36.0±10.3μmol/L respectively. After 3 months of chemotherapy, the free carnitine level was significantly decreased. The free carnitine level after 3 months of chemotherapy was lower than that before therapy in 13 patients (76.5%). The groups of patients with serum free carnitine lower than (n=9) and above (n=8) the standard level were compared. GFS showed significant improvement at 3 months of levocarnitine treatment in the low carnitine group. However, significant improvement at 3 months of levocarnitine treatment in the standard carnitine group was not observed. Levocarnitine was effective for 88.9% (8/9) and 50.0% (4/8) of patients in the respective groups.\n　Levocarnitine supplementation may have a role as adjuvant therapy that improves QOL of patients with carnitine deficiency during chemotherapy. Our results show that serum free carnitine is reduced by chemotherapy in patients with urological cancer."}]},"item_10001_textarea_6":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"　今回我々は初の試みとして，泌尿器科領域癌における抗癌剤治療前後での血清カルニチン値を測定し，QOL への影響について検討した．さらに癌治療中の患者においてカルニチン補充が及ぼすQOL への効果について検討を加えた．\n　2016年６月１日から2018年９月30日までに当科で化学療法もしくは分子標的薬治療を行った泌尿器科領域癌患者17例を対象とした．抗癌剤治療前後での血清カルニチンを測定し，その後レボカルニチン1,500 mg/ 日の経口投与を行い，QOL についてprospective に評価を行った．抗癌剤治療前，治療３カ月，レボカルニチン経口投与１カ月，３カ月の４ポイントで血清遊離カルニチンを測定し，QOL については Brief Fatigue Inventory（ BFI）を用いた global fatigue score（GFS）で評価した．\n　年齢中央値は69歳（52～82歳）で男女比は12：５であった．疾患は尿路上皮癌が10例，前立腺癌が５例，腎癌が２例であった．\n　治療内容は尿路上皮癌に対するgemcitabine/cisplatin が10例，前立腺癌に対するdocetaxel が３例，cabazitaxel が１例，etoposide/cisplatin が１例，腎癌に対する分子標的薬（sunitinib，pazopanib）が２例であった．血清遊離カルニチンは，抗癌剤治療前：49.0±12.1μmol/L，抗癌剤治療後：36.0±10.3μmol/L と抗癌剤治療後に統計学的に有意な低下を認めた（p<0.05）．\n　また抗癌剤治療前と比して17例中13例（76.5％）が，抗癌剤治療３カ月でカルニチンの低下を認めた．血清遊離カルニチン値が基準値未満に低下した症例（<36μmol/L）をカルニチン低値群（n=9），基準値を保っていた症例をカルニチン非低値群（n=8）として２群間について検討した．カルニチン低値群においてレボカルニチン内服３カ月で，内服前と比して統計学的に有意なGFSの低下が認められ，QOL の改善が得られた（p<0.05）．一方，カルニチン非低値群では，レボカルニチン内服前後でGFS に差異は認めなかった．またレボカルニチン内服３カ月でGFS が改善した症例をレボカルニチン有効例とすると，カルニチン低値群で88.9％（8/9）が有効，カルニチン非低値群で50.0％（4/8）が有効であった．\n　抗癌剤治療中のカルニチン欠乏症では，カルニチン補充でQOL の改善が期待できると考えられた．レボカルニチンは泌尿器科領域癌患者の治療の際に補助薬の一端を担うことが期待される．また泌尿器科領域癌患者において，抗癌剤治療によって血清遊離カルニチン値が低下することが示唆された．"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"月森, 翔平","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"原, 綾英","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"藤井, 智浩","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"宮地, 禎幸","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"永井, 敦","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TSUKIMORI, Shohei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HARA, Ryoei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUJII, Tomohiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MIYAJI, Yoshiyuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAGAI, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-01"}],"displaytype":"detail","filename":"KMJ-J201945111.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/2179/files/KMJ-J201945111.pdf"},"version_id":"f50a2d4a-9cc4-4e30-bfde-437dc3c01209"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"カルニチン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"レボカルニチン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"化学療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"尿路上皮癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"シスプラチン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Carnitine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Levocarnitine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Urothelial cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cisplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"泌尿器科領域癌患者におけるレボカルニチン投与のQOL に関する初期検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"泌尿器科領域癌患者におけるレボカルニチン投与のQOL に関する初期検討","subitem_title_language":"ja"},{"subitem_title":"A preliminary study of QOL of levocarnitine administration for patients with urologic cancer","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"31","path":["686"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-04-01"},"publish_date":"2020-04-01","publish_status":"0","recid":"2179","relation_version_is_last":true,"title":["泌尿器科領域癌患者におけるレボカルニチン投与のQOL に関する初期検討"],"weko_creator_id":"31","weko_shared_id":-1},"updated":"2024-04-19T04:11:18.244753+00:00"}